Skip to main
BNTX
BNTX logo

BioNTech SE (BNTX) Stock Forecast & Price Target

BioNTech SE (BNTX) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 42%
Buy 33%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

BioNTech's oncology pipeline, which includes diverse classes of drugs such as mRNA-based therapies and bispecific antibodies, demonstrates the company's robust commitment to innovative cancer treatments, fostering a strong growth potential in this segment. The incremental progress of BNT323 within the global Phase 3 DYNASTY-Breast02 trial suggests a favorable outlook, aligning with the company's strategy to solidify its position in targeted cancer immunotherapy. Additionally, advancements in the LP.8.1-adapted monovalent COVID-19 vaccine, which shows enhanced immune responses against evolving SARS-CoV-2 variants, further solidify BioNTech's relevance in the vaccine market, reinforcing overall positive momentum for the company's financial trajectory.

Bears say

BioNTech faces several significant risks that contribute to a negative outlook, including potential negative data from multiple clinical programs and slower-than-anticipated market acceptance of its products. The company may struggle to maintain investor confidence in its oncology pipeline due to heightened attention on its COVID-19 vaccine, which is subject to changing regulatory and market conditions. Additionally, risks related to partnerships, mergers and acquisitions, regulatory compliance, and long-term dilution could further weaken its financial stability and growth prospects.

BioNTech SE (BNTX) has been analyzed by 12 analysts, with a consensus rating of Buy. 42% of analysts recommend a Strong Buy, 33% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BioNTech SE and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BioNTech SE (BNTX) Forecast

Analysts have given BioNTech SE (BNTX) a Buy based on their latest research and market trends.

According to 12 analysts, BioNTech SE (BNTX) has a Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $136.45, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $136.45, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BioNTech SE (BNTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.